文献速递妇科

血清miRNA提高多变量指数检测对附件肿块分诊的准确性

Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
PubMed 文献 · Gynecol Oncol · 2024-08-23

本研究纳入678例受试者(286例癌症、392例对照),将7种蛋白标志物、180种miRNA及年龄和绝经状态纳入神经网络模型。联合模型在内部验证集(AUC=0.9;95%CI 0.81-0.95)和外部验证集(AUC=0.95;95%CI 0.90-0.98)上优于单用miRNA或蛋白联合元数据。外部验证中联合模型总体敏感性92%、特异性80%,早期和晚期癌症敏感性分别为80%和100%。

要点

  • 联合miRNA、蛋白标志物、年龄和绝经状态的模型提高了附件肿块分诊准确性。
  • 外部验证集AUC=0.95(95%CI 0.90-0.98),总体敏感性92%、特异性80%。
  • 早期和晚期癌症敏感性分别为80%和100%,早期浆液性卵巢癌敏感性78%。

核心结论

  • 联合miRNA、蛋白标志物、年龄和绝经状态的多模态检测可改善附件肿块的手术分诊。

研究设计与样本

  • 研究纳入468例训练受试者(191例癌症病例和277例良性附件肿块对照或健康对照),分析7种蛋白标志物和180种miRNA。
  • 将循环分析物数据与年龄和绝经状态(元数据)结合纳入神经网络模型,以分类样本为病例或对照。
  • 采用十折交叉验证的前向回归最小化模型维度并最大化病例与对照间的线性分离。
  • 模型验证使用内部验证集(44例病例和56例对照)和外部验证集(51例病例和59例对照)。
  • 总研究人群为678例受试者,包括286例病例和392例对照;290例(43%)为绝经前。

主要发现

  • 由10种miRNA组成的面板与蛋白及元数据特征结合时表现最佳。
  • 联合模型在内部验证集(AUC=0.9;95%CI 0.81-0.95)和外部验证集(AUC=0.95;95%CI 0.90-0.98)上优于单用miRNA或蛋白联合元数据(不含miRNA)。
  • 外部验证中联合模型总体敏感性92%、特异性80%。
  • 外部验证中早期和晚期癌症敏感性分别为80%和100%。
  • 外部验证中早期浆液性卵巢癌敏感性78%,早期非浆液性癌敏感性82%。

临床怎么用

  • 原文结论认为联合miRNA、蛋白标志物、年龄和绝经状态的多模态检测可改善附件肿块的手术分诊。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether a multimodal assay combining serum microRNA with protein biomarkers and metadata improves triage assessment of an adnexal mass. METHODS: Serum samples from 468 training subjects (191 cancer cases and 277 benign adnexal mass controls or healthy controls) were analyzed for seven protein biomarkers and 180 miRNA. Circulating analyte data were combined with age and menopausal status (metadata) into a neural network model to classify samples as cases or controls. Forward regression with ten-fold cross-validation minimized the dimensionality of the model while maximizing linear separation between cases and controls. Model validation proceeded using both internal (44 cases and 56 controls) and external validation sets (51 cases and 59 controls). RESULTS: The total study population comprised 678 subjects, including 286 cases and 392 controls. Overall, 290 (43%) of the subjects were premenopausal. A panel of 10 miRNA delivered optimal performance when combined with protein and metadata features. The combined model improved the Receiver Operator Characteristic Area Under the Curve (ROC AUC) on the internal (AUC = 0.9; 95% CI 0.81-0.95) and external validation sets (AUC = 0.95; 95% CI 0.90-0.98) compared to miRNA alone or proteins plus metadata (without miRNA). On external validation, the combined model offered 92% sensitivity at 80% specificity overall, with 80% and 100% sensitivity for early and late-stage cancers, respectively, including 78% sensitivity for early-stage, serous ovarian cancers and 82% sensitivity for early-stage, non-serous cancers. CONCLUSIONS: A multimodal assay combining miRNA with protein biomarkers, age, and menopausal status improves surgical triage of an adnexal mass.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Webber JW, Wollborn L, Mishra S, et al. Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass. Gynecol Oncol. 2024. PMID: 39180961. doi:10.1016/j.ygyno.2024.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。